文献类型：期刊文献

英文题名：miR-21-5p targets SKP2 to reduce osteoclastogenesis in a mouse model of osteoporosis

作者：Huang, Yizhen[1,2];Yang, Yute[1,2];Wang, Jianle[1,2];Yao, Shasha[1,2];Yao, Teng[1,2];Xu, Yining[3];Chen, Zizheng[1,2];Yuan, Putao[1,2];Gao, Jun[1,2];Shen, Shuying[1,2];Ma, Jianjun[1,2]

机构：[1]Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China;[2]Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Peoples R China;[3]Shaoxing Univ, Sch Med, Shaoxing, Peoples R China

年份：2021

卷号：296

外文期刊名：JOURNAL OF BIOLOGICAL CHEMISTRY

收录：SCI-EXPANDED(收录号：WOS:000672866400588)、、EI(收录号：20211710261359)、Scopus(收录号：2-s2.0-85104670439)、WOS

基金：This work was supported by Medical Healthy Scientific Technology Project of Zhejiang Province (2020388803, 2020RC070, WKJ-ZJ-1906), National Natural Science Foundation of China (81972504, 81802680, 81972089, 81972504, 81871797, 81874015, 81871796, 81802147), Zhejiang Provincial Natural Science Foundation of China (LY19H160058, Z20H060003, Q20H160293, Q20H160237), National Key R&D Program of China (No. 2018YFC1105202, 2019YFC110055), the Key research and development plan in Zhejiang province (No. 2018C03060, 2020C03041).

语种：英文

外文关键词：Diseases - Drug interactions - Mammals - Polymerase chain reaction - RNA

外文摘要：Osteoporosis results from an imbalance between bone formation and bone resorption. Traditional drugs for treating osteoporosis are associated with serious side effects, and thus, new treatment methods are required. This study investigated the role of differentially expressed microRNAs during osteoclast differentiation and osteoclast activity during osteoarthritis as well as the associated underlying mechanisms. We used a microarray to screen microRNAs that decreased in the process of osteoclast differentiation and verified miR-21-5p to decrease significantly using RT-qPCR. In follow-up experiments, we found that miR-21-5p targets SKP2 to regulate osteoclast differentiation. In vivo, ovariectomized mice were used to simulate perimenopausal osteoporosis induced by estrogen deficiency, and miR-21-5p treatment inhibited bone resorption and maintained bone cortex and trabecular structure. These results suggest that miR-21-5p is a new therapeutic target for osteoporosis.